November 2020

CorLog Probe 1P in times of COVID-19

emka MEDICAL GmbH has developed an innovative technology for measuring invasive pressures. The focus is on measuring blood pressures. The main goal of using this technology is to monitor and adapt therapy for general heart failure. On the way there, emka MEDICAL is also exploring other applications such as structural heart diseases (tricuspid valve insufficiency), cardiac support systems and pulmonary arterial hypertension (PAH). The development goes from short-term applications of up to 30 days to long-term applications in which CorLog is implanted.

In the future, CorLog Probe 1P could also play a role in the fight against COVID-19. COVID-19 often increases the flow resistance of the lungs and thus the pressure (pulmonary artery pressure), see figure 1. According to guidelines for pulmonary arterial hypertension (PAH), this should be examined with a right heart catheterization. This complex procedure, which is also stressful for the heart valves, only provides one-time information. Using CorLog Probe 1P not only saves you this procedure, you also get continuous and mobile pressure values of up to 30 days. These pressures can then be used to adjust pharmaceutical therapy to bring PAH under control.

Figure 1: COVID-19 effects that can lead to pulmonary hypertension and right heart failure [1].

Pulmonary hypertension [1] can also damage the right ventricle [3] [4] and cause right heart failure [1] [2]. Both pulmonary hypertension and changes in the right ventricle can be measured using CorLog [5], see also figure 2.

Figure 2: Right ventricular pressure (black) and part of the curve that is common with pulmonary artery pressure (red). Localization of the area with the help of the first time derivative of the pressure.

In contrast to other solutions, patients can be mobilized with CorLog. This can be used to carry out stress tests which can be monitored wirelessly with CorLog.

The use of CorLog for severe courses of COVID-19 with pulmonary hypertension is currently being investigated by intensive care physicians. Publications are planned.

Quotes:

[1] Park JF, Banerjee S, Umar S. In the eye of the storm: the right ventricle in COVID-19. Pulm Circ. 2020;10(3):2045894020936660. Published 2020 Jul 2. doi:10.1177/2045894020936660

[2] Argulian E, Sud K, Vogel B, et al. Right Ventricular Dilation in Hospitalized Patients with COVID-19 Infection [published online ahead of print, 2020 May 15]. JACC Cardiovasc Imaging. 2020;10.1016/j.jcmg.2020.05.010. doi:10.1016/j.jcmg.2020.05.010

[3] Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41(39):3827-3835. doi:10.1093/eurheartj/ehaa664

[4] Li Y, Li H, Zhu S, et al. Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19 [published online ahead of print, 2020 Apr 28].JACC Cardiovasc Imaging. 2020;S1936-878X(20)30342-9. doi:10.1016/j.jcmg.2020.04.014

[5] Karamanoglu M, Bennett T, Ståhlberg M, et al. Estimation of cardiac output in patients with congestive heart failure by analysis of right ventricular pressure waveforms. Biomed Eng Online. 2011;10:36. Published 2011 May 13. doi:10.1186/1475-925X-10-36